Fatal adenovirus infection during alemtuzumab (anti-CD52 monoclonal antibody) treatment of a patient with fludarabine-refractory B-cell chronic lymphocytic leukemia |
| |
Authors: | Cavalli-Björkman Nina Osby Eva Lundin Jeanette Kalin Mats Osterborg Anders Gruber Astrid |
| |
Affiliation: | (1) Department of Hematology and Oncology, Karolinska Hospital, Stockholm, Sweden;(2) Department of Infectious Diseases, Karolinska Hospital, Stockholm, Sweden |
| |
Abstract: | Alemtuzumab (Campath-1H) is a humanized CD52 monoclonal antibody that targets normal as well as malignant B- and T-lymphocytes. Alemtuzumab has significant antitumor activity in chronic lymphocytic leukemia (B-CLL) but also induces immunosuppression. We describe a case of fatal adenovirus infection in a heavily pretreated patient with fludarabine-refractory B-CLL receiving alemtuzumab therapy, drawing attention to the fact that also viruses other than cytomegalovirus (CMV) and herpes simplex (HSV) need to be considered in B-CLL patients with fever of unknown origin while on alemtuzumab treatment. |
| |
Keywords: | Adenovirus alemtuzumab Campath-1H chronic lymphocytic leukemia |
本文献已被 PubMed SpringerLink 等数据库收录! |